Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.  Our goal is to overcome resistance, improve response to treatment and increase overall survival.  We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. 

Biotechnology

Cardiff Oncology

Cardiff Oncology's headquarters in San Diego, CA, United States

Mark Erlander

Tod Smeal

Roger Sidhu

Vicki Kelemen

James Levine

Lâle White

James O. Armitage

Gary W. Pace

Eric Van-Cutsem

Christoph Reinhard

Josep Tabernero

Amer Zeidan

Mani Mohindru

Renee P. Tannenbaum

Glenn J. Bubley

David Einstein

Michael B. Yaffe

Heinz-Josef Lenz

Gary Jacob

Rodney S. Markin

The Advisory Team at Cardiff Oncology provides expert guidance and strategic insights to support the development and clinical advancement of onvansertib. Comprised of experienced advisors and independent directors, the team leverages their extensive knowledge in oncology and clinical research to help address medical needs, overcome treatment resistance, and improve patient outcomes.

Advisory Team

The Finance Team at Cardiff Oncology is responsible for managing the company's financial planning, analysis, and reporting. They oversee budgeting, accounting, and regulatory compliance to ensure the financial stability and integrity of the organization. The team supports strategic decision-making by providing financial insights and ensuring effective resource allocation to advance the development of their cancer treatment, onvansertib.

Finance Team

The Leadership Team at Cardiff Oncology drives the strategic direction and decision-making necessary to advance the company’s mission of developing innovative cancer treatments. Comprising key executives such as the CEO, CFO, and CSO, this team oversees regulatory strategies, financial management, and scientific research initiatives, ensuring that the development of onvansertib and other therapeutics aligns with the company’s goals of improving patient outcomes and addressing critical medical needs in oncology.

Leadership Team

The Research and Development Team at Cardiff Oncology is responsible for innovating and advancing the company's lead candidate, onvansertib. This team focuses on exploring combinatorial therapies using onvansertib with standard-of-care chemotherapy and targeted therapeutics, conducting preclinical and clinical research, analyzing genomic data to understand treatment responses, managing clinical trials, and ensuring the progression of development programs to overcome cancer resistance and improve patient outcomes.

Research and Development Team

Cardiff Oncology

Org chart

Board & advisors

Teams

Advisory Team

Finance Team

Leadership Team

Research and Development Team

Offices

Cardiff Oncology

Org chart

Board & advisors

Teams

Advisory Team

Finance Team

Leadership Team

Research and Development Team

Offices

Related companies